Track bills, resolutions, and amendments moving through Congress
Stop Pills That Kill Act
The bill strengthens tools, coordination, and transparency to curb illegal pill production and reduce overdose risk, but does so by imposing new compliance costs, recordkeeping burdens, and expanded criminal exposure that could affect manufacturers, sellers, buyers, taxpayers, and defendants.
Combating Illicit Xylazine Act
The bill strengthens federal authority, surveillance, and reporting to address xylazine supply and harms—potentially improving public-health and enforcement responses—but does so at the cost of increased criminalization risk, new burdens on legitimate medical and veterinary users, added agency and taxpayer costs, and transitional uncertainty.
Measuring Illicit Fentanyl Trafficking Act
The bill strengthens DHS coordination and accountability to interdict illicit fentanyl more effectively, but it raises privacy risks and administrative burdens and could incentivize short‑term performance over longer‑term investigative strategies.
Stop Chinese Fentanyl Act of 2025
The bill strengthens U.S. tools, transparency, and targeted authorities to disrupt fentanyl supply chains while preserving ordinary goods trade, but it risks diplomatic escalation, new compliance and administrative costs, and constraints on some executive sanctions options.
HALT Fentanyl Act
The bill strengthens and speeds federal authority to target fentanyl-related substances—likely reducing availability and aiding enforcement—while imposing broader Schedule I coverage and accelerated rulemaking that may hinder legitimate research, raise compliance and enforcement costs, and increase risks of overbroad prosecutions.
HALT Fentanyl Act
The bill trades faster, broader legal tools and clearer definitions to deter and prosecute fentanyl-related substances and to allow some research continuity, against expanded criminal exposure, tighter research constraints and administrative/compliance burdens that may raise costs and limit access for researchers, providers, and some patients.
Expressing support for the designation of February 23, 2025, to March 1, 2025, as "National Fentanyl Awareness Week" and raising awareness of the negative impacts of fentanyl in the United States.
The bill increases attention to fentanyl's lethal risk and could strengthen prevention, testing, and enforcement coordination, but it also risks steering resources toward punitive border and law-enforcement responses and fueling fear that may undercut treatment, harm reduction, and civil liberties.
Supporting the goals and ideals of Red Ribbon Week during the period of October 23 through October 31, 2025.
The resolution raises public awareness and promotes safe disposal and prevention messaging around fentanyl and other drugs, but its emphasis on symbolic actions and enforcement narratives risks diverting attention and resources from evidence‑based treatment and harm‑reduction, and may increase stigma for people who use drugs.
Designating August 21, 2025, as "Fentanyl Prevention and Awareness Day".
The resolution creates a national day to raise awareness and spotlight prevention partners—potentially improving coordination and education—but it is symbolic without funding and may unintentionally increase stigma or criminalization if not paired with concrete harm-reduction and treatment measures.
Commending Federal, State, and local law enforcement for their efforts in protecting Americans by combating drug trafficking and agroterrorism and for their recent actions in Kansas and across the country.
The resolution emphasizes enforcement and interdiction to protect public health, agriculture, and community safety, but does so at the potential cost of higher public spending and heightened civil‑liberties and treatment‑funding concerns.
Supporting the mission and goals of National Fentanyl Awareness Day in 2025, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.
The resolution raises awareness and supports documenting fentanyl threats to protect youth and guide agencies, but it risks creating alarm and encouraging punitive responses without committing funding or emphasizing treatment and harm reduction.
Joint Task Force to Counter Illicit Synthetic Narcotics Act of 2025
The bill centralizes and strengthens federal coordination, intelligence, and prosecutorial tools to disrupt synthetic‑opioid supply chains—potentially improving public safety and treatment deployment—while raising costs, civil‑liberty and privacy risks, oversight and federalism concerns, and diplomatic and local‑burden tradeoffs.
BUST FENTANYL Act
The bill strengthens U.S. tools and reporting to disrupt fentanyl and meth supply chains—especially those linked to the PRC—giving law enforcement faster sanctions and more focused intelligence at the cost of increased diplomatic tension, economic and compliance burdens for businesses, potential legal ambiguity, and higher administrative obligations.
HIDTA Enhancement Act
The bill channels sustained funding and DOJ support to strengthen law-enforcement responses to fentanyl trafficking and improve data-driven targeting, but it increases federal spending and carries risks of local resource diversion, prosecutorial disruption, and civil-liberties concerns if safeguards and offsets are not put in place.
Temporary Extension of Fentanyl-Related Substances Scheduling Act
Extending emergency scheduling keeps fentanyl analogues harder to obtain and preserves fast-acting enforcement tools, but it constrains research and imposes extra compliance and government costs.
Overdose RADAR Act
The bill strengthens overdose detection, coordination, and harm‑reduction/treatment capacity through federal grants and legal protections (faster, more targeted public‑health action) at the cost of increased ongoing local costs, administrative burdens, privacy risks, and potential shifts toward enforcement and regulatory uncertainty.
OPIOIDS Act
The bill aims to improve overdose detection, lab capacity, and interagency coordination—helping target public-health and enforcement responses—but increases privacy and civil‑liberty risks, may burden small labs or exclude under-resourced jurisdictions, and could shift spending toward enforcement rather than treatment.
Caribbean Border Counternarcotics Strategy Act
The bill centralizes and strengthens coordinated Caribbean counternarcotics efforts—potentially improving security and reducing violence in U.S. territories—while likely increasing federal costs and raising civil‑liberty and local‑policing trade-offs.
Combating Illicit Xylazine Act
The bill tightens federal control and enforcement for xylazine and creates reporting mechanisms to inform policy — improving enforcement consistency and public-health data while risking increased criminalization, higher compliance costs, access challenges for legitimate medical/veterinary uses, and short-term enforcement complexities.
End Gas Station Heroin Act
The bill reduces public exposure to highly potent synthesized kratom derivatives and similar synthetic opioids and strengthens federal enforcement while imposing compliance costs, access restrictions for some patients, and legal uncertainty that could burden small businesses and research.
Cannabis Administration and Opportunity Act
The bill shifts cannabis out of Schedule I and builds a broad federal regulatory, research, and reinvestment framework that expands economic and justice benefits for affected communities while imposing substantial new federal spending, compliance costs, and transitional legal and privacy risks.
Nitrous Oxide Inhalation Prevention Act
The bill prioritizes reducing youth nitrous‑oxide misuse and building prevention/oversight capacity, but does so at the cost of increased regulatory and compliance burdens for businesses and agencies, potential privacy impacts for purchasers, uncertain federal spending, and possible access impacts for legitimate medical and food‑service uses.
SAFE Banking Act of 2026
The bill substantially expands banking, payment, and mortgage access for state‑sanctioned cannabis and hemp markets and increases regulatory clarity, at the cost of higher compliance burdens, privacy/surveillance trade‑offs, persistent federal–state legal tensions, and some increased taxpayer or financial‑stability exposure.
Turn the Tide Act
The bill directs substantial new, multi‑year federal funding and several policy changes to expand opioid prevention, treatment, recovery housing, and workforce support—improving access for many in high‑burden areas—but does so at significant federal and state cost, with uneven geographic effects and added administrative and implementation complexity.
Fairness in Fentanyl Sentencing Act of 2025
The bill strengthens enforcement and rapid sentencing updates for fentanyl-related import/export offenses and funds postal detection to reduce mailed opioids, but it increases risks of broader criminalization, higher costs, operational burdens, reduced public input, and privacy and mail-delay impacts.
Amend the Internal Revenue Code of 1986 to maintain the prohibition on allowing any deduction or credit associated with a trade or business involved in trafficking marijuana.
The bill clarifies and tightens federal tax rules to prevent taxpayers from subsidizing federally prohibited marijuana operations, but does so by imposing significantly higher tax burdens and regulatory friction on state-legal cannabis businesses, risking business closures, informal operations, and financial access problems.
PRESS Act
The bill strengthens criminal penalties to reduce illegally imported pill‑produced drugs and give prosecutors clearer tools, but it raises legal uncertainty and compliance risk for legitimate manufacturers and exporters and could increase federal enforcement and incarceration costs.
Hemp Safety Enforcement Act
The bill increases State and Tribal control over hemp regulation and preserves interstate market access, at the cost of creating legal complexity, higher compliance burdens, and a likely patchwork of standards that could complicate supply chains and confuse consumers.
TIME for Overdose Justice Act
The bill removes time limits for prosecuting drug offenses that cause death or serious injury, strengthening the ability to hold distributors criminally accountable and potentially deterring deadly drug distribution, but it does so at the cost of increased exposure of accused individuals to stale prosecutions, greater prosecutorial leverage, and shifted DOJ resources.
Protect Law Enforcement Task Forces Act
The bill centralizes and accelerates federal, prosecutor-led efforts against transnational organized crime—likely improving large-scale investigations and seizures—but does so at the risk of incentivizing asset-driven enforcement, stretching or redirecting resources, narrowing agency flexibility, and deprioritizing public-health alternatives to reduce demand.
